Bimekizumab 3-year Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Long-term Pooled Analysis from Five Phase 3/3b Trials. J of Skin. 2024;8(1):s305. doi:10.25251/skin.8.supp.305